Biome Australia Ltd

Biome Australia's capital structure shows a debt-to-equity ratio of 0.66, indicating moderate leverage. The company's liquidity position is characterized by a current ratio of 1.59, suggesting it can cover its short-term liabilities with its current assets. However, the company's operating cash flow is negative at -2,819,660 AUD, which raises concerns about its ability to generate sufficient cash from operations to service its debt and fund operations. In terms of profitability, Biome Australia's return on equity (ROE) is 4.59%, and its return on assets (ROA) is 1.79%. These figures are below the typical thresholds for pharmaceutical companies, which often aim for ROE above 10% and ROA above 5%. The company's gross profit margin is 61.1%, which is relatively strong, but its operating margin is only 1.17%, indicating high operating expenses relative to revenue. The company's revenue is concentrated in its own brands, Activated Nutrients and Activated Probiotics, with no disclosed geographic diversification. This concentration increases the risk associated with market fluctuations in the microbiome health sector. The company's product portfolio includes a range of clinically backed precision probiotics, which are marketed for various health concerns, including low mood, sleep, bone health, and irritable bowel syndrome. Biome Australia's growth trajectory is modest, with a revenue of 18,417,190 AUD. The company's outlook for the current fiscal year is not explicitly provided, but the high price-to-earnings (P/E) ratio of 302.71 and price-to-book (P/B) ratio of 13.9 suggest that the market is valuing the company's future growth potential highly relative to its current earnings and book value. The company's free cash flow of 256,250 AUD indicates some capacity to reinvest in growth or return value to shareholders, but the negative operating cash flow is a concern. The risk assessment for Biome Australia highlights a medium liquidity risk and a low dilution risk. The company's net cash is negative after subtracting total debt, which could impact its ability to meet short-term obligations. The company's capital expenditure of -200,380 AUD suggests that it is not investing heavily in new projects or infrastructure, which may limit its long-term growth potential. Recent events and filings do not provide specific details on new product launches or strategic partnerships, but the company's focus on evidence-based live biotherapeutics and complementary medicines aligns with growing consumer interest in microbiome health. The company's high price targets from analysts, all set at 1.00 AUD, indicate a positive outlook despite the current financial challenges.